Pasithea Therapeutics to Present at H.C. Wainwright Annual Global Investment Conference

Pasithea Therapeutics Corp. will participate in the H.C. Wainwright 27th Annual Global Investment Conference in New York City. CEO Dr. Tiago Reis Marques will give a live company presentation and management will be available for one-on-one meetings. Pasithea is developing PAS-004, a next-generation macrocyclic MEK inhibitor for RASopathies treatment.

Pasithea Therapeutics Corp. (NASDAQ: KTTA) has announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference, scheduled to take place from September 8-10, 2025, in New York City. The biotech company will present its lead drug candidate, PAS-004, a next-generation macrocyclic MEK inhibitor, to investors and financial professionals.

CEO Dr. Tiago Reis Marques will deliver a live company presentation on September 10, 2025, at 2:30 PM ET at the Lotte New York Palace Hotel. Management will also be available for one-on-one meetings throughout the event, providing an opportunity for attendees to discuss the company's progress and future plans.

Pasithea Therapeutics is currently developing PAS-004 for the treatment of RASopathies, MAPK pathway-driven tumors, and other diseases. The company is conducting Phase 1 clinical trials for PAS-004 in advanced cancer patients (NCT06299839) and in adult patients with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas (NCT06961565).

The conference is expected to attract a diverse range of investors and industry experts, providing a valuable platform for Pasithea to showcase its innovative pipeline and engage with potential partners and investors.

References:
[1] https://www.stocktitan.net/news/KTTA/pasithea-therapeutics-to-present-at-the-h-c-wainwright-27th-annual-shsx7jet6h2l.html